• TG Therapeutics recently reported positive Phase 1 data showing that a high‑concentration subcutaneous formulation of BRIUMVI in relapsing multiple sclerosis achieved supportive pharmacokinetic, pharmacodynamic, safety, and tolerability results compared with the approved intravenous version, backing ongoing Phase 3 trials of quarterly and every‑other‑month dosing.
• The data suggest subcutaneous BRIUMVI could support at‑home administration via an autoinjector while maintaining non‑inferior drug exposure and B‑cell depletion relative to IV infusions, potentially reshaping how patients receive the therapy.
• We’ll now examine how the promising subcutaneous BRIUMVI profile, including potential at-home dosing, may influence TG Therapeutics’ investment narrative.

This technology could replace computers: discover 29 stocks that are working to make quantum computing a reality.

TG Therapeutics Investment Narrative Recap

To own TG Therapeutics today, you have to believe BRIUMVI can remain a durable MS franchise while the company broadens access and indications without eroding profitability. The key near term catalyst is the Phase 3 subcutaneous BRIUMVI readout in late 2026 or early 2027, and these positive Phase 1 RMS data directly support that program. The biggest current risk remains TG’s dependence on BRIUMVI amid intensifying anti CD20 and self administered competition.

Among the recent updates, the completed enrollment and ongoing Phase 3 trial of subcutaneous BRIUMVI in RMS ties most directly to this news. The new Phase 1 data strengthen the case that quarterly or every other month subcutaneous dosing could meet the trial’s non inferiority exposure endpoint, which is central to the planned subcutaneous launch catalyst and to mitigating the risk that payers and patients increasingly favor competing self administered therapies.

Yet even as subcutaneous BRIUMVI advances, investors should be aware that pricing pressure and payer pushback could still...

TG Therapeutics' narrative projects $1.5 billion revenue and $461.7 million earnings by 2029.

Uncover how TG Therapeutics' forecasts yield a $44.43 fair value, a 8% downside to its current price.

Exploring Other Perspectives

While consensus assumes a smoother path, the lowest analysts were modeling 2029 earnings of about US$402.4 million and a 7x P/E, highlighting how concerns over rising costs and patent cliffs could leave you with a far more cautious view of TG than the new subcutaneous BRIUMVI data might initially suggest.

Explore 7 other fair value estimates on TG Therapeutics - why the stock might be worth over 4x more than the current price!

Form Your Own Verdict

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
• Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 46 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.